Skip to Main Content

Author Details

Julia E Maxson
Knight Cancer Institute, Oregon Health & Science University
2009
44
20
PMIDPaper TitleJournal TitlePublished Year
36526735Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors.Leukemia2023
37116708Mutational screens highlight glycosylation as a modulator of colony-stimulating factor 3 receptor (CSF3R) activity.J Biol Chem2023
36976323Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.Mol Cancer Res2023
36579444A novel colony stimulating factor 3 receptor activating mutation identified in a patient with chronic neutrophilic leukemia.Haematologica2023
36894620RUNX1::ETO translocations must precede CSF3R mutations to promote acute myeloid leukemia development.Leukemia2023
35200567Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia.Curr Oncol2022
35710794Author Correction: Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.Nat Commun2022
35794242Correction: Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.Leukemia2022
35788238GoPeaks: histone modification peak calling for CUT&Tag.Genome Biol2022
35590033PU.1 and MYC transcriptional network defines synergistic drug responses to KIT and LSD1 inhibition in acute myeloid leukemia.Leukemia2022
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
34002029Mutant SETBP1 enhances NRAS-driven MAPK pathway activation to promote aggressive leukemia.Leukemia2021
33830192A new role for hematoxylin: targeting CALR.Blood2021
33516272Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report.Biomark Res2021
34504101TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.Nat Commun2021
32471953Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.Proc Natl Acad Sci U S A2020
31844143Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.Leukemia2020
31880950Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.J Clin Oncol2020
32187354Prognostic impact of CSF3R mutations in favorable risk childhood acute myeloid leukemia.Blood2020
31366621Genomic landscape of neutrophilic leukemias of ambiguous diagnosis.Blood2019
31784538Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.Nat Commun2019
29572350Gain-of-function mutations in granulocyte colony-stimulating factor receptor (CSF3R) reveal distinct mechanisms of CSF3R activation.J Biol Chem2018
30018082Synthetic lethality of TNK2 inhibition in PTPN11-mutant leukemia.Sci Signal2018
30348809A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia.Cancer Res2018
28028025Genomics of chronic neutrophilic leukemia.Blood2017
28630439Recurrent cyclin D2 mutations in myeloid neoplasms.Leukemia2017
27072365Neogenin Facilitates the Induction of Hepcidin Expression by Hemojuvelin in the Liver.J Biol Chem2016
26475333The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.Clin Cancer Res2016
26677978Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.Cancer Res2016
26389776Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series.Leuk Lymphoma2016
27143256CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.Blood2016
26032424Therapeutically Targetable ALK Mutations in Leukemia.Cancer Res2015
24403076Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization.J Biol Chem2014
25628989Acute promyelocytic leukemia with JAK2 V617F and severe differentiation syndrome.Leuk Res Rep2014
25180155Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia.Leuk Res Rep2014
23733748Cancer- and endotoxin-induced cachexia require intact glucocorticoid signaling in skeletal muscle.FASEB J2013
24081659The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.Blood2013
23896413The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.Blood2013
23604229CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.Leukemia2013
23656643Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.N Engl J Med2013
23031643Expression of myeloid differentiation factor 88 in neurons is not requisite for the induction of sickness behavior by interleukin-1β.J Neuroinflammation2012
20122714The cell giveth and the cell taketh away: an overview of Notch pathway activation by endocytic trafficking of ligands and receptors.Acta Histochem2011
20937842Matriptase-2- and proprotein convertase-cleaved forms of hemojuvelin have different roles in the down-regulation of hepcidin expression.J Biol Chem2010
19029439Processing of hemojuvelin requires retrograde trafficking to the Golgi in HepG2 cells.Blood2009
  • 1 - 44 of 44

Recommended Authors

Jonathan M Ahmann
Huntsman Cancer Institute, The University of Utah
Career Start Year 2017
Number of shared co-authors 10
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc.
Career Start Year 2010
Number of shared co-authors 2
Dongqing Yan
Inner Mongolia University
Career Start Year 2010
Number of shared co-authors 15
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Alisa Damnernsawad
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2009
Number of shared co-authors 22
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 0
Felicitas Thol
Hannover Medical School
Career Start Year 2007
Number of shared co-authors 8
Christopher Y Park
NYU Robert I. Grossman School of Medicine
Career Start Year 2006
Number of shared co-authors 4
Yana Pikman
Dana Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 7
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Career Start Year 2004
Number of shared co-authors 16
Anna L Brown
Adelaide Medical School, University of Adelaide
Career Start Year 2003
Number of shared co-authors 7
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 2
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 4
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 6
Ravindra Majeti
Stanford University School of Medicine
Career Start Year 1998
Number of shared co-authors 14
Lukas D Wartman
Washington University School of Medicine in St. Louis
Career Start Year 1998
Number of shared co-authors 4
Stephanie Halene
Smilow Cancer Center, Yale University School of Medicine
Career Start Year 1997
Number of shared co-authors 4
Stefan Fr??hling
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Career Start Year 1996
Number of shared co-authors 8
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 6
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 12
Lucy A Godley
The University of Chicago
Career Start Year 1994
Number of shared co-authors 10
Matthew J Walter
Washington University School of Medicine in St. Louis
Career Start Year 1994
Number of shared co-authors 9
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 10
Seishi Ogawa
Kyoto University
Career Start Year 1993
Number of shared co-authors 6
Timothy A Graubert
Massachusetts General Hospital
Career Start Year 1993
Number of shared co-authors 9
Benjamin S Braun
Benioff Children's Hospitals, University of California san francisco
Career Start Year 1992
Number of shared co-authors 1
Derek L Stirewalt
Fred Hutchinson Cancer Center
Career Start Year 1992
Number of shared co-authors 14
Scott A Armstrong
Boston Children's Hospital
Career Start Year 1990
Number of shared co-authors 9
Toshio Kitamura
The University of Tokyo.
Career Start Year 1984
Number of shared co-authors 0
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Career Start Year 1980
Number of shared co-authors 24

Collaborators

Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 20
Brian J Druker
Oregon Health & Science University
Co-authored papers 17
Theodore P Braun
Oregon Health & Science University
Co-authored papers 15
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 10
Cody Coblentz
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 9
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 8
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Samuel B Luty
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Sarah A Carratt
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Zachary Schonrock
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 7
Melissa L Abel
National Cancer Institute, National Institutes of Health
Co-authored papers 6
Daniel J Coleman
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 6
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 6
Amy Foley
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 5
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Kim-Hien T Dao
Astex Pharmaceuticals
Co-authored papers 5
Joseph Estabrook
Cancer Early Detection Advanced Research Center, Oregon Health & Science University
Co-authored papers 5
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 4
Richard D Press
Oregon Health and Science University
Co-authored papers 4
Rhonda E Ries
Clinical Research Division, Fred Hutchinson Cancer Research Center
Co-authored papers 4
Samantha L Savage
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Bill H Chang
Oregon Health and Science University
Co-authored papers 4
Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers 4
Stephen T Oh
Washington University School of Medicine
Co-authored papers 4
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 4
Soheil Meshinchi
Fred Hutchinson Cancer Research Centre
Co-authored papers 4
Jason D MacManiman
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 3
Release 1.2